Consecutive successful pregnancies subsequent to intravenous immunoglobulin therapy in a patient with recurrent spontaneous miscarriage

Michael F Diejomaoh 1, Zainab Bello 2, Waleed Al Jassar 1, Jiri Jirous 2, Kavitha Karunakaran 2, Asiya T Mohammed 3

Affiliations

12 November 2015

-

doi: 10.2147/IMCRJ.S93159

Abstract

Background: Recurrent spontaneous miscarriage (RSM) has a multifactorial etiology, mainly due to karyotype abnormalities including balanced translocation, anatomical uterine disorders, and immunological factors, although in 50%-60% the etiology is unexplained. The treatment of RSM remains challenging, and the role of intravenous immunoglobulin (IVIG) in RSM is controversial.

Case report: Mrs HM, 37 years old, obstetric summary: P0+1+13+1, a known case of hypothyroidism/polycystic ovary syndrome, married to an unrelated 47-year-old man, presented to our RSM clinic in early January 2014 for investigation and treatment. She has had multiple failed in vitro fertilization trials and 13 first-trimester missed miscarriages terminating at 6-7 weeks, all without IVIG therapy. Her tenth pregnancy was spontaneous, managed in London, UK, with multiple supportive therapy and courses of IVIG starting from the third to the 30th week of pregnancy. The pregnancy ended at 36 weeks of gestation with a cesarean section and a live girl baby was delivered. Mrs HM had balanced translocation, 46XX t (7:11) (p10:q10). Preimplantation genetic diagnosis/intracytoplasmic sperm injection/in vitro fertilization was performed with embryo transfer on May 29, 2014, and resulted in a successful pregnancy. She was commenced immediately on metformin, luteal support, and IVIG therapy, started at 6 weeks of gestation and at monthly intervals until 30 weeks of gestation, and also received additional therapy. The pregnancy was monitored with ultrasound, progressed uneventfully until admission at 35 weeks of gestation, with mildly elevated liver enzymes and suspected fetal growth restriction. She was managed conservatively, and in the light of nonreassuring fetal status, a live female infant weighing 2.29 kg was delivered by emergency cesarean section on January 14, 2015, with an Apgar score of 8 and 9 and mild respiratory distress, and was admitted to the Special Care Baby Unit for intensive therapy. The mother and baby made satisfactory progress and were discharged on January 24, 2015.

Conclusion: Two consecutive successful pregnancies in Mrs HM with multiple causes of RSM treated with other medications and IVIG strongly suggest that IVIG has a positive role in RSM.

Keywords: intravenous immunoglobulin; miscarriage; pregnancy outcome; recurrent.

Similar articles

Pregnancy outcomes after assisted human reproduction.

Okun N, Sierra S; GENETICS COMMITTEE; SPECIAL CONTRIBUTORS.J Obstet Gynaecol Can. 2014 Jan;36(1):64-83. doi: 10.1016/S1701-2163(15)30685-X.PMID: 24444289

Successful Pregnancy and Delivery at Term Following Intravenous Immunoglobulin Therapy with Heparin for Unexplained Recurrent Pregnancy Loss Suspected of Immunological Abnormalities: A Case Report and Brief Literature Review.

Mitsui J, Ota K, Takayanagi Y, Nako Y, Tajima M, Fukui A, Kawai K.J Clin Med. 2023 Feb 4;12(4):1250. doi: 10.3390/jcm12041250.PMID: 36835786 Free PMC article.

Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial.

Yamada H, Deguchi M, Saito S, Takeshita T, Mitsui M, Saito T, Nagamatsu T, Takakuwa K, Nakatsuka M, Yoneda S, Egashira K, Tachibana M, Matsubara K, Honda R, Fukui A, Tanaka K, Sengoku K, Endo T, Yata H.EClinicalMedicine. 2022 Jun 29;50:101527. doi: 10.1016/j.eclinm.2022.101527. eCollection 2022 Aug.PMID: 35795714 Free PMC article.

Live birth of monochorionic triamniotic triplets after in vitro fertilization and blastocyst transfer: case report and review of the literature.

Radwan P, Radwan M, Kobielska L, Sikora J.Ginekol Pol. 2014 Feb;85(2):154-7. doi: 10.17772/gp/1707.PMID: 24745163 Review.

A review of reproductive outcomes of women with two consecutive miscarriages and no living child.

Green DM, O'Donoghue K.J Obstet Gynaecol. 2019 Aug;39(6):816-821. doi: 10.1080/01443615.2019.1576600. Epub 2019 Apr 22.PMID: 31006300 Review.

Cited by

Metformin may induce immunologic tolerance at the maternal-foetal interface in early human pregnancy.

Fu X, Xiao L, Wu H, Li M, Zeng Y.Am J Transl Res. 2023 Mar 15;15(3):1807-1819. eCollection 2023.PMID: 37056854 Free PMC article.

The spectrum of chromosomal translocations in the Arab world: ethnic-specific chromosomal translocations and their relevance to diseases.

Zedan HT, Ali FH, Zayed H.Chromosoma. 2022 Sep;131(3):127-146. doi: 10.1007/s00412-022-00775-2. Epub 2022 Jul 30.PMID: 35907041 Free PMC article. Review.

The placental gateway of maternal transgenerational epigenetic inheritance.

Sailasree SP, Srivastava S, Mishra RK.J Genet. 2017 Jul;96(3):465-482. doi: 10.1007/s12041-017-0788-5.PMID: 28761010 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multi-centered randomized placebo-controlled trial. Hum Reprod. 2010;25:2203–2209. - PMC - PubMed
  2.  
    1. Daya S, Gunby J, Porter F, Scott J, Clark DA. Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage. Hum Reprod Update. 1999;5:475–482. - PubMed
  3.  
    1. Ata B, Tan SL, Shehata F, Hozler H, Buckett W. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. Fertil Steril. 2011;95:1080–1085. - PubMed
  4.  
    1. Reagan L. A prospective study of spontaneous abortion. In: Beard RW, Sharp F, editors. Early Pregnancy Loss: Mechanisms of Treatment. London: Springer-Verlag; 1988. pp. 23–27.
  5.  
    1. Wilcox AJ, Weinberg CR, O’Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319:189–194. - PubMed
  6.  
    1. Alberman E. The epidemiology of repeated abortions. In: Beard RW, Sharp F, editors. Early Pregnancy Loss: Mechanisms of Treatment. London: Springer-Verlag; 1988. pp. 9–17.
  7.  
    1. Christiansen OB, Pederson B, Rosgaard A, Husth M. A randomized; double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence of a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod. 2002;17:809–816. - PubMed
  8.  
    1. Rai R, Reagan L. Recurrent miscarriage. Lancet. 2006;368:601–611. - PubMed
  9.  
    1. Diejomaoh MF. Recurrent spontaneous miscarriage is still a challenging, diagnostic and therapeutic quagmire. Med Princ Pract. 2015;24(Suppl I):38–55. - PMC - PubMed
  10.  
    1. The practice committee of the American Society for Reproductive medicine Evaluation and treatment of recurrent pregnancy loss. A committee opinion. Fertil Steril. 2012;98:1103–1111. - PubMed
  11.  
    1. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2010;93:1234–1243. - PubMed
  12.  
    1. Brezina PR, Kutteh WH. Classic and cutting-edge strategies for the management of early pregnancy loss. Obst Gynecol Clin North Am. 2014;4:1–18. - PubMed
  13.  
    1. Shapira E, Ratzon R, Shoham-Vardi I, Serjienko R, Mazor M, Bashiri A. Primary versus secondary recurrent pregnancy loss-epidemiological characteristics, etiology, and next pregnancy outcome. J Perinat Med. 2012;40:389–396. - PubMed
  14.  
    1. Diejomaoh MF, Al-Azemi M, Jirous J, et al. The aetiology and pattern of recurrent pregnancy loss. J Obstet Gynaecol. 2002;22:62–67. - PubMed
  15.  
    1. Porter TF, La Coursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2006;2:CD000112. - PubMed
  16.  
    1. Quenby S, Bates M, Doig T, et al. Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod. 1999;14:2386–2391. - PubMed
  17.  
    1. King K, Smith S, Chapman M, Sacks G. Detailed analysis of peripheral blood natural killer [NK] cells in women with recurrent miscarriage. Hum Reprod. 2010;25:52–58. - PubMed
  18.  
    1. Christiansen OB, Larsen EC, Egerup P, Lunoee L, Egestad L, Nielsen HS. Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. BJOG. 2015;122:500–508. - PubMed
  19.  
    1. Clifford K, Flanagan AM, Reagan L. Endometrial CD56+ natural killer cells in women with recurrent miscarriage: a histomorphometric study. Hum Reprod. 1999;14:2727–2730. - PubMed
  20.  
    1. Ramos-Medina R, García-Segovia A, Gil J, et al. Experience in IVIg therapy for selected women with recurrent reproductive failure and NK cell expansion. Am J Reprod Immunol. 2014;71:458–466. - PubMed
  21.  
    1. Aoki K, Kajiura S, Matsumoto Y, et al. Preconceptional natural killer – cell activity as a predictor of miscarriage. Lancet. 1995;345:1340–1342. - PubMed
  22.  
    1. Yamada H, Morikawa M, Kato EH, Shimada S, Kobashi G, Minakami H. Pre-conceptional natural killer cell activity and percentage as predictors of biochemical pregnancy and spontaneous abortion with normal chromosome karyotype. Am J Reprod Immuol. 2003;50:351–354. - PubMed
  23.  
    1. Perricone R, Di Muzio G, Perricone C, et al. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulin. Am J Reprod Immunol. 2006;55:232–239. - PubMed
  24.  
    1. Silver RM. Intravenous immune globulin: another disappointing treatment for pregnancy loss. BJOG. 2015;122:509. - PubMed
  25.  
    1. Christiansen OB, Mathiesen O, Husth M, et al. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions with IV. Immunoglobulin. Hum Reprod. 1995;19:2690–2695. - PubMed
  26.  
    1. Stephenson MD, Dreher K, Honlihan E, Wu V. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double blinded, placebo-controlled trial. Am J Reprod Immunol. 1998;39:82–88. - PubMed
  27.  
    1. Jablonowska B, Selbing A, Palfi M, Ernerudh J, Kjellberg S, Lindton B. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Hum Reprod. 1999;14:838–841. - PubMed
  28.  
    1. Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol. 2012;67:296–303. - PubMed
  29.  
    1. Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for recurrent spontaneous miscarriage: a systemic review. BJOG. 2007;114:134–142. - PubMed
  30.  
    1. Marquard K, Westphal LM, Milki AA, Lathi RB. Etiology of recurrent pregnancy loss in women over the age of 35 years. Fertil Steril. 2010;94:1473–1477. - PubMed
  31.  
    1. Moraru M, Carbone J, Alecsandru D, et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expended CD 56+ cells. Am J Reprod Immunol. 2012;68:75–84. - PubMed
  32.  
    1. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17:2858–2864. - PubMed
  33.  
    1. Szekeres-Bartho J. Immunologic relationship between the mother and fetus. Intern Rev Immunol. 2002;21:471–496. - PubMed
  34.  
    1. Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005;112:1096–1101. - PubMed
  35.  
    1. Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril. 2014;102:1357–1363. - PubMed
  36.  
    1. Leong H, Stachnik J, Bonk ME, Matuszewski MS. Unlabeled uses of intravenous immunoglobulin. Am J Health Syst Pharm. 2008;65:1815–1824. - PubMed

Page Navigation